阿斯利康近日宣布，计划在中国投资超过1000亿元人民币，以进一步扩大其在中国市场的研发、生产和商业运营规模。此次投资将重点聚焦于创新药物研发、生物制药生产、人工智能医疗技术以及绿色低碳供应链建设等多个领域。中国是全球第二大医药市场，阿斯利康此次大规模投资不仅体现了其对中国市场长期增长的信心，也显示出其深化本土合作、推动健康创新的战略决心。该投资有望为中国带来更多前沿治疗方案，提升生物医药产业能力，并进一步促进中国与全球医疗健康的协同发展。
AstraZeneca recently announced plans to invest over 100 billion RMB in China to further expand its R&D, production, and commercial operations in the Chinese market. The investment will focus on multiple areas including innovative drug research, biopharmaceutical manufacturing, AI-powered medical technology, and building green, low-carbon supply chains. As the world’s second-largest pharmaceutical market, China represents a key growth region for AstraZeneca. This major investment not only demonstrates the company’s long-term confidence in China’s market potential but also underscores its strategic commitment to deepening local partnerships and advancing healthcare innovation. The move is expected to bring more cutting-edge treatments to patients, enhance local biopharmaceutical capabilities, and further promote collaboration between China and the global healthcare community.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/24400.html